Under pressure from the FDA, Endo will voluntarily pull its opioid painkiller Opana ER from the market.

A controversy over Sanofi's Zika vaccine candidate may spawn pricing limits for all treatments developed with the help of Defense Department funding.

The FDA slapped a clinical hold on two Keytruda trials, dashing Merck's hopes of combining the IO star with one of Celgene's big-selling myeloma meds.

Two pharma companies are increasing cancer drug prices, and one analyst says it’s evidence drugmakers sometimes raise prices simply “because they can.”

In the wake of last week's canceled buyout, Stada's CEO and CFO have left the company, and new buyout talk has already sprung up.

Eli Lilly has won a nod from NICE for its anticipated blockbuster and Humira competitor, Olumiant, a drug the FDA rejected in April.

Brazilian authorities have asked Bayer to recall more than a dozen lots of its Gynera birth control pills.

One prominent pharma CEO figures overhauling healthcare won't take a few weeks of work. Think years—even decades.

Merck’s cholesterol med anacetrapib delivered a surprise win in its cardiovascular outcomes trial. Did it win big enough to make a launch worthwhile?

An FDA warning letter has been issued to a CMO that made belladonna-treated teething products that the agency warned may cause seizures in infants.